Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Sangro, Chan, Kelley, Lau, Kudo, Sukeepaisarnjaroen, Yarchoan, De Toni, Furuse, Kang, Galle, Rimassa, Heurgué, Tam, Van Dao, Thungappa, Breder, Ostapenko, Reig, Makowsky, Paskow, Gupta, Kurland, Negro, Abou-Alfa, (2024) Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Ann Oncol (IF: 56.7) 35(5) 448-457Links
http://www.ncbi.nlm.nih.gov/pubmed/38382875http://dx.doi.org/10.1016/j.annonc.2024.02.005
